ORCID as entered in ROS

Select Publications
2023, 'BARRIER TO PROGRESS: DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) INDUCES A TIGHTENED BLOOD-BRAIN BARRIER PHENOTYPE.', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, CANADA, Vancouver, Vol. 25, presented at 28th Annual Scientific Meeting of the Society-for-Neuro-Oncology (SNO), CANADA, Vancouver, 15 November 2023 - 19 November 2023
,2023, 'Targeting the epigenome through combined Facilitates Chromatin Transcription (FACT) and Bromodomain and Extra-Terminal Domain (BET) inhibition in Diffuse Midline Glioma (DMG)', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, MN, Minneapolis, Vol. 84, presented at AACR Special Conference on Brain Cancer, MN, Minneapolis, 19 October 2023 - 22 October 2023, http://dx.doi.org/10.1158/1538-7445.BRAIN23-B016
,2023, 'COGNITIVE, ACADEMIC, AND QUALITY OF LIFE OUTCOMES IN SURVIVORS OF PEDIATRIC LOW-GRADE GLIOMA: CHALLENGING THE 'BENIGN TUMOR' PERCEPTION.', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, DC, Washington, Vol. 25, presented at 7th Pediatric Neuro-Oncology Research Conference, DC, Washington, 22 June 2023 - 24 June 2023, http://dx.doi.org/10.1093/neuonc/noad073.221
,2023, 'Tumour profiling frequently informs the interpretation of germline variants arising from paired analysis in children and young people', in EUROPEAN JOURNAL OF HUMAN GENETICS, SPRINGERNATURE, SCOTLAND, Glasgow, Vol. 32, pp. 572 - 572, presented at 56th Annual Conference of the European-Society-of-Human-Genetics (ESHG), SCOTLAND, Glasgow, 10 June 2023 - 13 June 2023
,2023, 'ACT001 AND CBL0137: A VIABLE COMBINATION THERAPEUTIC FOR DIFFUSE INTRINSIC PONTINE GLIOMAS', in PEDIATRIC BLOOD & CANCER, WILEY, Vol. 70, pp. S153 - S153
,2022, 'PARENTS' AND PATIENTS' UNDERSTANDING OF A PRECISION MEDICINE TRIAL FOR HIGH-RISK CHILDHOOD CANCER', in PEDIATRIC BLOOD & CANCER, WILEY, Vol. 69, pp. S399 - S399, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000859203901450&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2022, 'PRECISION MEDICINE REVEALS A HETEROGENOUS TUMOUR IMMUNE MICROENVIRONMENT IN PAEDIATRIC GLIOMAS', in PEDIATRIC BLOOD & CANCER, WILEY, Vol. 69, pp. S327 - S328, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000859203901292&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2022, 'COPPER CHELATION THERAPY TARGETS S-ADENOSYLMETHIONINE (SAM) METABOLISM AND EPIGENETIC REGULATORS IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, GERMANY, Hamburg, Vol. 24, pp. 22 - 22, presented at 20th International Symposium on Pediatric Neuro-Oncology (ISPNO) / Annual Meeting of the Brain-Tumor-Group-of-SIOP-Europe (SIOPE-BTG), GERMANY, Hamburg, 11 June 2022 - 15 June 2022
,2022, 'DIPG CELLS ALTER THE PERMEABILITY OF THE BLOOD-BRAIN BARRIER IN THE BRAINSTEM LEADING TO TREATMENT FAILURE', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, GERMANY, Hamburg, Vol. 24, pp. 22 - 22, presented at 20th International Symposium on Pediatric Neuro-Oncology (ISPNO) / Annual Meeting of the Brain-Tumor-Group-of-SIOP-Europe (SIOPE-BTG), GERMANY, Hamburg, 11 June 2022 - 15 June 2022
,2022, 'DUAL CTLA4/PD-1 BLOCKADE IMPROVES SURVIVAL FOR REPLICATION-REPAIR DEFICIENT HIGH-GRADE GLIOMAS FAILING SINGLE AGENT PD-1 INHIBITION: AN IRRDC STUDY', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, GERMANY, Hamburg, Vol. 24, pp. 84 - 84, presented at 20th International Symposium on Pediatric Neuro-Oncology (ISPNO) / Annual Meeting of the Brain-Tumor-Group-of-SIOP-Europe (SIOPE-BTG), GERMANY, Hamburg, 11 June 2022 - 15 June 2022
,2022, 'EXPLORING THE ROLE OF THE EPIGENETIC FACTOR H2A.Z ACETYLATION IN DIPG', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, GERMANY, Hamburg, Vol. 24, pp. 26 - 27, presented at 20th International Symposium on Pediatric Neuro-Oncology (ISPNO) / Annual Meeting of the Brain-Tumor-Group-of-SIOP-Europe (SIOPE-BTG), GERMANY, Hamburg, 11 June 2022 - 15 June 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000840122400096&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2022, 'THE CHILDHOOD BRAIN CANCER CELL LINE ATLAS: A RESOURCE FOR BIOMARKER IDENTIFICATION AND THERAPEUTIC DEVELOPMENT', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, GERMANY, Hamburg, Vol. 24, pp. 172 - 172, presented at 20th International Symposium on Pediatric Neuro-Oncology (ISPNO) / Annual Meeting of the Brain-Tumor-Group-of-SIOP-Europe (SIOPE-BTG), GERMANY, Hamburg, 11 June 2022 - 15 June 2022
,2022, 'ATRT-17. A phase II study of continuous low dose panobinostat in paediatric patients with malignant rhabdoid tumours and atypical teratoid rhabdoid tumours.', in Neuro-Oncology, Oxford University Press (OUP), Vol. 24, pp. i6 - i7, http://dx.doi.org/10.1093/neuonc/noac079.016
,2022, 'DIPG-06. Uncovering the FACTs in Diffuse Midline Glioma (DMG)', in Neuro-Oncology, Oxford University Press (OUP), Vol. 24, pp. i18 - i18, http://dx.doi.org/10.1093/neuonc/noac079.063
,2022, 'DIPG-08. The development of ACT001 as a novel therapeutic for diffuse intrinsic pontine gliomas', in Neuro-Oncology, Oxford University Press (OUP), Vol. 24, pp. i19 - i19, http://dx.doi.org/10.1093/neuonc/noac079.065
,2022, 'DIPG-20. Copper chelation therapy targets S-adenosylmethionine (SAM) metabolism and epigenetic regulators in diffuse intrinsic pontine glioma (DIPG)', in Neuro-Oncology, Oxford University Press (OUP), Vol. 24, pp. i22 - i22, http://dx.doi.org/10.1093/neuonc/noac079.077
,2022, 'DIPG-37. Exploring the role of the epigenetic factor H2A.Z acetylation in DIPG', in Neuro-Oncology, Oxford University Press (OUP), Vol. 24, pp. i26 - i27, http://dx.doi.org/10.1093/neuonc/noac079.094
,2022, 'FIREFLY-1 (PNOC 026): A phase 2 study to evaluate the safety and efficacy of tovorafenib (DAY101) in pediatric patients with RAF-altered recurrent or progressive low-grade glioma or advanced solid tumors.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. TPS10062 - TPS10062, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.tps10062
,2022, 'PATTERNS OF CEREBROSPINAL FLUID DIVERSION AND SURVIVAL IN CHILDREN WITH DIFFUSE INTRINSIC PONTINE GLIOMA: A REPORT FROM THE INTERNATIONAL DIFFUSE INTRINSIC PONTINE GLIOMA REGISTRY', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, Vol. 24, pp. 23 - 24, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000840122400084&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2022, 'THE DEVELOPMENT OF ACT001 AS A NOVEL THERAPEUTIC FOR DIFFUSE INTRINSIC PONTINE GLIOMAS', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, Vol. 24, pp. 19 - 19, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000840122400067&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2022, 'UNCOVERING THE FACTS IN DIFFUSE MIDLINE GLIOMA (DMG)', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, Vol. 24, pp. 18 - 18, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000840122400065&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2022, 'Designing for implementation: co-design of a paediatric oncology medicines database (ProCure) to support complex care provision for children with a hard-to-treat cancer', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 18, pp. 229 - 229
,2022, 'Immunotherapy: IN VITRO STUDIES IN SUPPORT OF GD2-SPECIFIC CAR-T CELL THERAPY FOR AGGRESSIVE ADULT AND PEDIATRIC BRAIN TUMORS', in Cytotherapy, Elsevier BV, Vol. 24, pp. S125 - S125, http://dx.doi.org/10.1016/s1465-3249(22)00336-x
,2021, 'Abstract 3044: The unexplored immune landscape of high-risk pediatric cancers', in Cancer Research, American Association for Cancer Research (AACR), Vol. 81, pp. 3044 - 3044, http://dx.doi.org/10.1158/1538-7445.am2021-3044
,2021, 'ACT001-A PROMISING THERAPEUTIC FOR DIFFUSE INTRINSIC PONTINE GLIOMAS', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, Vol. 23, pp. 20 - 20, http://dx.doi.org/10.1093/neuonc/noab090.080
,2021, 'HGG-10. THE BLOOD-BRAIN BARRIER IN DIPG: INVESTIGATING REGION-SPECIFIC DIFFERENCES IN PERMEABILITY', in Neuro-Oncology, Oxford University Press (OUP), Vol. 23, pp. i19 - i19, http://dx.doi.org/10.1093/neuonc/noab090.076
,2021, 'POLYAMINE PATHWAY INHIBITION IS A POTENT NOVEL THERAPEUTIC STRATEGY AGAINST DIFFUSE INTRINSIC PONTINE GLIOMA', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, Vol. 23, pp. 40 - 41, http://dx.doi.org/10.1093/neuonc/noab090.163
,2021, 'POTENTIAL NEW THERAPIES FOR DIFFUSE INTRINSIC PONTINE GLIOMAS IDENTIFIED THROUGH HIGH THROUGHPUT DRUG SCREENING', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, Vol. 23, pp. 42 - 42, http://dx.doi.org/10.1093/neuonc/noab090.169
,2021, 'TARGETING FACILITATES CHROMATIN TRANSCRIPTION (FACT) AS A NOVEL STRATEGY THAT ENHANCES RESPONSE TO HISTONE DEACETYLASE (HDAC) INHIBITION IN DIPG', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, Vol. 23, pp. 18 - 19, http://dx.doi.org/10.1093/neuonc/noab090.075
,2021, 'The unexplored immune landscape of high-risk pediatric cancers.', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, PA, Philadelphia, Vol. 81, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), PA, Philadelphia, 10 April 2021 - 21 May 2021
,2020, 'DDEL-12. NANOPARTICLE DELIVERY OF DOXORUBICIN FOR THE TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)', in Neuro-Oncology, Oxford University Press (OUP), Vol. 22, pp. iii286 - iii286, http://dx.doi.org/10.1093/neuonc/noaa222.047
,2020, 'DIPG-07. HIGH THROUGHPUT DRUG SCREENING IDENTIFIES POTENTIAL NEW THERAPIES FOR DIFFUSE INTRINSIC PONTINE GLIOMAS (DIPGs)', in Neuro-Oncology, Oxford University Press (OUP), Vol. 22, pp. iii288 - iii288, http://dx.doi.org/10.1093/neuonc/noaa222.058
,2020, 'DIPG-14. TARGETING POLO-LIKE KINASE 1 IN COMBINATION WITH KEY ONCOGENIC DRIVERS IN DIPG: FROM SINGLE AGENT TO COMBINATION STRATEGIES', in Neuro-Oncology, Oxford University Press (OUP), Vol. 22, pp. iii289 - iii289, http://dx.doi.org/10.1093/neuonc/noaa222.064
,2020, 'DIPG-15. POLYAMINE PATHWAY INHIBITION IS A POTENT NOVEL THERAPEUTIC STRATEGY AGAINST DIFFUSE INTRINSIC PONTINE GLIOMA', in Neuro-Oncology, Oxford University Press (OUP), Vol. 22, pp. iii289 - iii290, http://dx.doi.org/10.1093/neuonc/noaa222.065
,2020, 'DIPG-16. COMBINATION OF ARGININE DEPLETION AND POLYAMINE INHIBITION AS AN ANTICANCER STRATEGY FOR DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)', in Neuro-Oncology, Oxford University Press (OUP), Vol. 22, pp. iii290 - iii290, http://dx.doi.org/10.1093/neuonc/noaa222.066
,2020, 'DIPG-27. TARGETING FACILITATES CHROMATIN TRANSCRIPTION (FACT) AS A NOVEL STRATEGY FOR DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) THAT ENHANCES RESPONSE TO HISTONE DEACETYLASE (HDAC) INHIBITION', in Neuro-Oncology, Oxford University Press (OUP), Vol. 22, pp. iii292 - iii292, http://dx.doi.org/10.1093/neuonc/noaa222.076
,2020, 'DIPG-29. PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE (PI3K) INHIBITION DRIVES PROTEIN KINASE C ACTIVATION (PKC) IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)', in Neuro-Oncology, Oxford University Press (OUP), Vol. 22, pp. iii292 - iii293, http://dx.doi.org/10.1093/neuonc/noaa222.078
,2020, 'COMBINATION OF ARGININE DEPLETION AND POLYAMINE INHIBITION AS AN ANTICANCER STRATEGY FOR DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, Vol. 22, pp. 290 - 290, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000606080100067&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'PRECISION MEDICINE FOR PAEDIATRIC HIGH-GRADE DIFFUSE MIDLINE GLIOMAS - RESULTS FROM THE ZERO CHILDHOOD CANCER COMPREHENSIVE PRECISION MEDICINE PROGRAM', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, Vol. 22, pp. 302 - 302, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000606080100118&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'Abstract A03: Prevalence and spectrum of germline mutations in children with high-risk cancer', in Cancer Research, American Association for Cancer Research (AACR), Vol. 80, pp. A03 - A03, http://dx.doi.org/10.1158/1538-7445.pedca19-a03
,2020, 'Abstract A52: Zero Childhood Cancer (ZERO): A comprehensive precision medicine platform for children with high-risk cancer', in Cancer Research, American Association for Cancer Research (AACR), Vol. 80, pp. A52 - A52, http://dx.doi.org/10.1158/1538-7445.pedca19-a52
,2020, 'Zero Childhood Cancer: A comprehensive precision medicine platform for children with high-risk cancer in Australia', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, ELECTR NETWORK, Vol. 80, presented at AACR Annual Meeting, ELECTR NETWORK, 22 June 2020 - 24 June 2020, http://dx.doi.org/10.1158/1538-7445.AM2020-SY09-02
,2019, 'Delta: A Parent and Patient Decision Aid to Support Clinical Trial Decision-Making in Childhood Cancer', in PEDIATRIC BLOOD & CANCER, WILEY, Vol. 66, pp. S118 - S118, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000488458001090&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'Zero Childhood Cancer: A Comprehensive Precision Medicine Platform for Children and Adolescents with High-Risk Cancer', in PEDIATRIC BLOOD & CANCER, WILEY, Vol. 66, pp. S504 - S505, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000488458005162&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'Molecular targeted therapies and precision medicine for children with neuroblastoma and other refractory malignancies', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, CANADA, Montreal, Vol. 80, pp. 23 - 24, presented at AACR Special Conference on the Advances in Pediatric Cancer Research, CANADA, Montreal, 17 September 2019 - 20 September 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000551367400013&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'Prevalence and spectrum of germline mutations in children with high-risk cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, CANADA, Montreal, Vol. 80, pp. 42 - 43, presented at AACR Special Conference on the Advances in Pediatric Cancer Research, CANADA, Montreal, 17 September 2019 - 20 September 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000551367400048&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'Zero Childhood Cancer (ZERO): A comprehensive precision medicine platform for children with highrisk cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, CANADA, Montreal, Vol. 80, pp. 70 - 71, presented at AACR Special Conference on the Advances in Pediatric Cancer Research, CANADA, Montreal, 17 September 2019 - 20 September 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000551367400096&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'Families' and healthcare professionals' uncertainties in the era of cancer precision medicine: results from PRISM', in EUROPEAN JOURNAL OF HUMAN GENETICS, NATURE PUBLISHING GROUP, SWEDEN, Gothenburg, Vol. 27, pp. 1172 - 1172, presented at 52nd Conference of the European-Society-of-Human-Genetics (ESHG), SWEDEN, Gothenburg, 15 June 2019 - 18 June 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000489313900238&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'RESULTS OF THE ZERO CHILDHOOD CANCER INTEGRA-TM PRECISION MEDICINE PLATFORM FOR PAEDIATRIC HIGH-RISK BRAIN TUMOURS', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, CA, San Francisco, Vol. 21, pp. 118 - 118, presented at 5th Biennial Conference of the Society-for-Neuro-Oncology on Pediatric Neuro-Oncology Basic and Translational Research, CA, San Francisco, 03 May 2019 - 04 May 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000473243700229&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'TARGETING PI3K USING THE BLOOD BRAIN BARRIER PENETRABLE INHIBITOR, GDC-0084, FOR THE TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, CA, San Francisco, Vol. 21, pp. 68 - 68, presented at 5th Biennial Conference of the Society-for-Neuro-Oncology on Pediatric Neuro-Oncology Basic and Translational Research, CA, San Francisco, 03 May 2019 - 04 May 2019, http://dx.doi.org/10.1093/neuonc/noz036.024
,